Compare Biogen Inc (BIIB) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Okta, Inc. — how do they compare? Biogen Inc trades at $208.77 (market cap $30.13B), while Okta, Inc. trades at $146.93 (market cap $26.13B). The key difference: Biogen Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| BIIB | OKTA | |
|---|---|---|
Market Cap | $30.13B | $26.13B |
Sector | Health | Technology |
52-Week High | $216.63 | $154.62 |
52-Week Low | $128.93 | $62.93 |
Enterprise Value | $37.20B | $23.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Okta trades at $147.43, down 2.22% today, with a bullish technical signal from moving averages but overbought RSI readings. The company achieved GAAP profitability in 2025 with $28M net income, marking a significant turnaround from prior losses. Recent earnings beats and the acquisition of Permiso Security for AI identity threat defense highlight growth momentum. Operating cash flow surged to $750M in 2025, supporting financial flexibility.
The outlook is positive with strong analyst support (73% buy ratings) and a consensus price target of $129.71, though the current price exceeds this. Risks include high valuation multiples (P/E 108.93) and competitive pressure from Microsoft. Revenue growth to $3.0B in 2026 forecasts sustained expansion, but investor caution is warranted near technical resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
